As filed with the Securities and Exchange Commission on June 9, 2004.
Registration No. 333-114600
----------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------------------
Amendment No. 1
to
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
----------------------------------------
DELCATH SYSTEMS, INC.
(Exact name of Issuer as specified in its charter)
1100 Summer Street
3rd Floor
Stamford, Connecticut 06905
(203) 323-8668
(Address, Including Zip Code, and Telephone Number, Including Area Code of
Registrant's Principal Executive Office)
M. S. Koly
President and Chief Executive Officer
Delcath Systems, Inc.
1100 Summer Street
3rd Floor
Stamford, Connecticut 06905
(203) 323-8668
----------------------------------------
Copies to:
Paul G. Hughes
Murtha Cullina LLP
Two Whitney Street
P.O. Box 704
New Haven, Connecticut 06503-0704
(203) 772-7726
----------------------------------------
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as
practicable after this Registration Statement becomes effective.
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, please check the following box. [X]
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier registration. If the delivery of
the prospectus is expected to be made pursuant to Rule 434, please check the
following box. [ ]
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a)
MAY DETERMINE.
Subject to Completion. Dated June 9, 2004
DELCATH SYSTEMS, INC.
Up to 5,969,490 Shares of Common Stock
This prospectus relates to two offerings of our common stock.
The first offering is a primary offering by us of up to 3,098,070 shares
that may be issued upon the exercise of warrants that we issued in 2000 and 2003
and that are currently publicly traded. We will receive the proceeds of any
exercise of these warrants. If all of these warrants were to be issued, we would
receive net proceeds of approximately $9.3 million (after our estimated expenses
of these offerings of $50,000) . Based on the recent prices of our common stock
on the Nasdaq SmallCap Market in comparison to the exercise price of the 2003
Warrants, we expect that we will elect to redeem the 2003 Warrants as promptly
as practicable. Based on those prices in comparison to the exercise price of our
2000 Warrants, we believe it is likely that few if any of the 2000 Warrants will
be exercised.
The second offering is the resale of:
o up to 1,879,626 shares that we issued in connection with the
exercise of warrants we issued as part of a private placement in
2002 and in private placements in 2004 (including shares that we
may issue upon exercise of the warrants we issued as part of the
private placements in 2004); and
o up to 991,784 shares that we might issue on the exercise of unit
warrants we issued to the underwriters of our public offerings
and of warrants that we might issue upon exercise of warrants
issued to the placement agents in our 2004 private placement.
If any of the shares described in the preceding paragraph are resold, we
will not receive any of the proceeds which will go to the person who sells the
shares.
The exercise prices of our 2004 Warrants, 2003 Warrants and 2000 Warrants
are subject to adjustment, including anti-dilution provisions for corporate
events, such as stock splits. It is possible that none of the 2004 Warrants, the
2003 Warrants or the 2000 Warrants will be exercised.
Our common stock is currently traded on the Nasdaq Small Cap Market and the
Boston Stock Exchange under the symbols "DCTH" and "DCT," respectively. Our 2000
Warrants currently trade on the Nasdaq Small Cap Market under the symbol "DCTW."
Our 2003 Warrants currently trade on the OTC Bulletin Board and the Boston Stock
Exchange under the symbols "DCTHZ" and "DCT&W," respectively. On June 4, 2004,
our common stock had a closing price of $2.20 per share, our 2003 Warrants had a
closing price of $1.40 per Warrant and our 2000 Warrants had a closing price of
$0.51 per Warrant.
Investing in our securities involves a high degree of risk. See "Risk Factors"
beginning on page 1 for factors you should consider before investing in our
securities.
-----------------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a
criminal offense.
-----------------------
The date of this prospectus is June __, 2004.
THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. NEITHER
WE NOR THE SELLING SHAREHOLDERS MAY SELL THESE SECURITIES UNTIL THE REGISTRATION
STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS
PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN
OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT
PERMITTED.
FOR CALIFORNIA INVESTORS
The offering of our Common Stock and the 2003 Warrants and the shares
offered on exercise of the 2003 Warrants was approved in California on the basis
of a limited offering qualification. Investors who are residents of California
must meet a "super suitability" standard of not less than $250,000 liquid net
worth (exclusive of home, home furnishings and automobiles), plus $65,000 gross
annual income or $500,000 liquid net worth of $1,000,000 net worth (inclusive of
home, home furnishings and automobiles) or $200,000 gross annual income. We did
not have to demonstrate compliance with some or all of the merit regulations of
the California Department of Corporations, as found in Title 10, California Code
of Regulations, Rule 260.140 et seq.
Residents of the State of California will be unable to sell shares of
common stock they purchase in this offering, and investors residing in all other
states will be unable to sell shares of common stock they purchase in this
offering to California residents, pursuant to exemptions for secondary trading
available under California Corporations Code Section 25104(h), as such
exemptions have been withheld. However, secondary sales may be made to
purchasers who meet the "super suitability" standqards or there may be other
exemptions to cover private sales by the bona fide owners of our securities for
such owners' own account without advertising and without being effected by or
through a broker dealer in a public offering.
TABLE OF CONTENTS
Page
RISK FACTORS...................................................................1
Risks Related to Our Business and Financial Condition.......................1
Risks Related to FDA and Foreign Regulatory Approval........................2
Risks Related to Manufacturing, Commercialization and Market
Acceptance of the Delcath System.......................................3
Risks Related to Patents, Trade Secrets and Proprietary Rights..............4
Risks Related to Products Liability.........................................5
Risks Related to an Investment in Our Securities............................5
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS..............................7
OUR BUSINESS...................................................................8
General.....................................................................8
Corporate Information.......................................................8
THE OFFERING...................................................................8
Terms of our Common Stock...................................................9
Terms of the 2004 Warrants.................................................10
Terms of the 2003 Warrants.................................................10
Terms of the 2000 Warrants.................................................10
Transfer Agent.............................................................11
USE OF PROCEEDS...............................................................11
SELLING SHAREHOLDERS..........................................................11
PLAN OF DISTRIBUTION..........................................................15
LEGAL MATTERS.................................................................16
EXPERTS.......................................................................17
WHERE CAN YOU FIND MORE INFORMATION...........................................17
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE...............................17
DISCLOSURE OF THE SEC'S POSITION ON INDEMNIFICATION FOR SECURITIES
ACT LIABILITIES............................................................18
No dealer, salesman or other person has been authorized to give any
information or to make any representations other than those contained or
incorporated in this prospectus. If given or made, such information or
representations must not be relied upon as having been authorized by Delcath
Systems, Inc., by the selling security holders or by any other person deemed to
be an underwriter. Neither the delivery of this prospectus nor any sale made
hereunder shall under any circumstances create an implication that the
information contained herein is correct as of any time subsequent to the date
hereof or that there has been no change in the affairs of Delcath Systems, Inc.
since the date hereof. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy the common stock or the warrants covered by this
prospectus by anyone in any jurisdiction in which such offer or solicitation is
not authorized or in which the person making such offer or solicitation is not
qualified to do so or to anyone to whom it is unlawful to make such offer or
solicitation.
In this prospectus, "Delcath," "we," "us" and "our" refer in each case to
Delcath Systems, Inc.
-i-
RISK FACTORS
You should consider carefully the following factors, as well as the other
information set forth in this prospectus, prior to making an investment in our
securities. If any of the following risks and uncertainties actually occur, our
business, financial condition or operating results may be materially and
adversely affected. In this event, the trading price of our securities, as
applicable, may decline and you may lose part or all of your investment.
Risks Related to Our Business and Financial Condition
The following factors relate to risks that are material to our business and
financial condition. If any of the possible events we describe below turns out
to be the case, our business may be adversely affected and we may be forced to
cease or curtail our operations which may result in the loss of your entire
investment.
Our entire focus has been the development and commercialization of the
Delcath system.
The Delcath system, an enabling technology for the isolation of various
organs in the body to permit the delivery of otherwise unacceptably toxic doses
of drugs, is our only product. If the Delcath system fails as a commercial
product, we have no other products to sell.
Continuing losses may exhaust our capital resources. We have no revenue to
date, a substantial accumulated deficit, recurring operating losses and negative
cash flow.
We expect to incur significant and increasing losses while generating
minimal revenues over the next few years. From our inception on August 5, 1988
through December 31, 2003, we have incurred cumulative losses of $18.2 million
which were principally incurred in connection with our product development
efforts. For the years ended December 31, 2002 and December 31, 2003, we
incurred net losses of $1.8 million and $2.3 million, respectively, and for the
quarters ended March 31, 2003 and March 31, 2004, we incurred net losses of
$531,000 and $710,000, respectively.
We have funded our operations through a combination of private placements
of our securities and through the proceeds of our public offerings in 2000 and
2003. Please see the detailed discussion of our various sales of securities
described in Note 2 to our 2003 financial statements that are included in our
Annual Report on Form 10-KSB for the year ended December 31, 2003. In addition,
we received gross proceeds of approximately $3.5 million from private placements
we completed in 2004 and approximately $229,000 on exercise of warrants in 2004
through March 31, 2004.
If we continue to incur losses we may exhaust our capital resources,
including those raised in this offering. As of March 31, 2004, we had cash and
cash equivalents and short term investments of $5.0 million.
We will likely need additional funding to complete our planned clinical
trials and our efforts to raise additional financing may be unsuccessful.
Our resources may not be sufficient to enable us to complete our Phase III
clinical trials and obtain FDA premarket approval for the use of doxorubicin
with our Delcath system because of unanticipated delays or expenses, increased
regulatory requirements by the FDA or other factors which we cannot foresee or
control. If we do not obtain any financing that we may require, we will not be
able to complete Phase III clinical trials or obtain FDA pre-marketing approval
for the use of doxorubicin with the Delcath system. Our ability to complete the
Phase III clinical trials could be lessened to the extent we devote assets to
clinical trials using melphalan with the Delcath system.
-1-
If we do not raise any additional capital that may be required to
commercialize the Delcath system, our potential to generate future revenues
will be significantly limited even if we receive FDA premarket approval.
Our current resources may not be sufficient to complete Phase III clinical
trials using doxorubicin and will be insufficient to fund the costs of
commercializing the Delcath system which will be significant. We have no
commitments for any additional financing. If we are unable to obtain additional
financing as needed, we will not be able to sell the system commercially.
Risks Related to FDA and Foreign Regulatory Approval
The following factors relate to risks that are material to obtaining FDA
and foreign regulatory approval. If any of the events we describe below turns
out to be the case, our business may be adversely affected and we may be forced
to cease or curtail our operations which may result in the loss of your entire
investment.
If the FDA refuses to grant premarket approval or limits the circumstances
under which the Delcath system may be used, our ability to market the
Delcath system will be greatly reduced.
Premarket approval requires a determination by the FDA that the data
developed by our clinical trials show that the use of doxorubicin in our system
is safe and effective in the treatment of primary liver cancer and melanoma
which has spread to the liver. The FDA requires that we demonstrate, for each of
primary liver cancer and metastatic melanoma, in a statistically rigorous
manner, increased patient survival times against a control group before it will
approve our application for premarket approval. Even if regulatory approval is
granted, the approval may limit the uses for which the Delcath system may be
marketed. If we fail to obtain FDA premarket approval, we will not be able to
market the Delcath system. Additionally, if we obtain FDA premarket approval
with substantial limitations on uses of the Delcath system, our ability to
market the system could be significantly reduced.
If we do not obtain FDA premarket approval, we may not be able to export
the Delcath system to foreign markets, which will limit our sales
opportunities.
If the FDA does not approve our application for premarket approval
application for the Delcath system, we will not be able to export the Delcath
system from the United States for marketing abroad unless approval has been
obtained from one of a number of developed nations. We have not begun to seek
foreign regulatory approval and may not be able to obtain approval from one or
more countries where we would like to sell the Delcath system. If we are unable
to market the Delcath system internationally because we are not able to obtain
required approvals, our international market opportunity will be materially
limited.
Because of our limited experience, conduct of Phase III clinical trials and
obtaining FDA premarket approval could be delayed.
We have experienced and may continue to experience delays in conducting and
completing the trials, caused by many factors, including our limited experience
in arranging for clinical trials and in evaluating and submitting the data
gathered from clinical trials, in designing trials to conform to the trial
protocols authorized by the FDA, in complying with the requirements of
institutional review boards at the sites where the trials will be conducted and
in identifying clinical test sites and sponsoring physicians. Completion of our
clinical trials will also depend on the ability of the clinical test sites to
identify patients to enroll in the clinical trials. The trials may also take
longer to complete because of difficulties we may encounter in entering into
agreements with clinical testing sites to conduct the trials. Any significant
delay in completing clinical trials or in the FDA's responding to our submission
or a requirement by the FDA for us to conduct additional trials would delay the
commercialization of the Delcath system and our ability to generate revenues.
-2-
Third-party reimbursement may not be available to purchasers of the Delcath
system or may be inadequate.
Physicians, hospitals and other health care providers may be reluctant to
purchase our system if they do not receive substantial reimbursement for the
cost of the procedures using our products from third-party payors, including
Medicare, Medicaid and private health insurance plans.
Because the Delcath system currently is characterized by the FDA as an
experimental device, Medicare, Medicaid and private health insurance plans will
not reimburse its use in the United States. We will not begin to seek to have
third-party payors reimburse the cost of the Delcath system until after its use
is approved by the FDA. Each third-party payor independently determines whether
and to what extent it will reimburse for a medical procedure or product.
Third-party payors in the United States or abroad may decide not to cover
procedures using the Delcath system. Further, third-party payors may deny
reimbursement if they determine that the Delcath system is not used in
accordance with established payor protocols regarding cost effective treatment
methods or is used for forms of cancer or with drugs not specifically approved
by the FDA.
New products are under increased scrutiny as to whether or not they will be
covered by the various healthcare plans and the level of reimbursement which
will be applicable to respective covered products and procedures. A third-party
payor may deny reimbursement for the treatment and medical costs associated with
the Delcath system, notwithstanding FDA or other regulatory approval, if that
payor determines that the Delcath system is unnecessary, inappropriate, not cost
effective, experimental or is used for a non-approved indication.
Risks Related to Manufacturing, Commercialization and Market Acceptance of the
Delcath System
We obtain necessary components for the Delcath system from sole-source
suppliers. Because manufacturers must demonstrate compliance with FDA
requirements, if our present suppliers fail to meet such requirements or if
we change any supplier, the successful completion of the clinical trials
and/or the commercialization of the Delcath system could be jeopardized.
We must ensure that the components of the Delcath system are manufactured
in accordance with manufacturing and performance specifications of the Delcath
system on file with the FDA and with drug and device good manufacturing practice
requirements. Many of the components of the Delcath system are manufactured by
sole source suppliers. If any of our suppliers fails to meet our needs, or if we
need to seek an alternate source of supply, we may be forced to suspend or
terminate our clinical trials. Further, if we need a new source of supply after
commercial introduction of the Delcath system, we may face long interruptions in
obtaining necessary components, which could jeopardize our ability to supply the
Delcath system to the market.
We do not have any contracts with suppliers for the manufacture of
components for the Delcath system. If we are unable to obtain an adequate
supply of the necessary components, we may not be able timely to complete
our clinical trials.
We do not have any contracts with suppliers for the manufacture of
components for the Delcath system. Certain components are available from only a
limited number of sources. To date, we have only had components of the Delcath
system manufactured for us in small quantities for use in pre-clinical studies
and clinical trials. We will require significantly greater quantities to
commercialize the product. If we are unable to obtain adequate supplies of
components from our existing suppliers or need to switch to an alternate
supplier, commercialization of the Delcath system could be delayed.
-3-
Because of our limited experience in marketing products and our lack of
adequate personnel to market and sell products, we may not be successful in
marketing and selling the Delcath system even if we receive FDA premarket
approval.
We have not previously sold, marketed or distributed any products and
currently do not have the personnel, resources, experience or other capabilities
to market the Delcath system adequately. Our success will depend upon our
ability to attract and retain skilled sales and marketing personnel. Competition
for sales and marketing personnel is intense, and we may not be successful in
attracting or retaining such personnel. Our inability to attract and retain
skilled sales and marketing personnel could adversely affect our business,
financial condition and results of operations.
Market acceptance of the Delcath system will depend on substantial efforts
and expenditures in an area with which we have limited experience.
Market acceptance of the Delcath system will depend upon a variety of
factors including whether our clinical trials demonstrate a significant
reduction in the mortality rate for the kinds of cancers treated on a
cost-effective basis, our ability to educate physicians on the use of the
Delcath system and our ability to convince healthcare payors that use of the
Delcath system results in reduced treatment costs to patients. We have only
limited experience in these areas and we may not be successful in achieving
these goals. Moreover, the Delcath system replaces treatment methods in which
many hospitals have made a significant investment. Hospitals may be unwilling to
replace their existing technology in light of their investment and experience
with competing technologies. Many doctors and hospitals are reluctant to use a
new medical technology until its value has been demonstrated. As a result, the
Delcath system may not gain significant market acceptance among physicians,
hospitals, patients and healthcare payors.
Rapid technological developments in treatment methods for liver cancer and
competition with other forms of liver cancer treatments could result in a
short product life cycle for the Delcath system.
Competition in the cancer treatment industry, particularly in the markets
for systems and devices to improve the outcome of chemotherapy treatment, is
intense. The Delcath system competes with all forms of liver cancer treatments
that are alternatives to the "gold standard" treatment of surgical resection.
Many of our competitors have substantially greater resources, especially
financial and technological. In addition, some of our competitors have
considerable experience in conducting clinical trials and other regulatory
procedures. These competitors are developing systems and devices to improve the
outcome of chemotherapy treatment for liver cancer. If these competitors develop
more effective or more affordable products or treatment methods, our
profitability will be substantially reduced and the Delcath system could have a
short product life cycle.
Risks Related to Patents, Trade Secrets and Proprietary Rights
Our success depends in large part on our ability to obtain patents,
maintain trade secret protection and operate without infringing on the
proprietary rights of third parties.
Because of the length of time and expense associated with bringing new
medical devices to the market, the healthcare industry has traditionally placed
considerable emphasis on patent and trade secret protection for significant new
technologies. Litigation may be necessary to enforce any patents issued or
assigned to us or to determine the scope and validity of third-party proprietary
rights. Litigation could be costly and could divert our attention from our
business. If others file patent applications with respect to inventions for
which we already have patents issued to us or have patent applications pending,
we may be forced to participate in interference proceedings declared by the
United States Patent and Trademark Office to determine priority of invention,
which could also be costly and could divert our attention from our business. If
a third party violates our intellectual property rights, we may be unable to
enforce our rights
-4-
because of our limited resources. Use of our limited funds to defend our
intellectual property rights may also affect our financial condition adversely.
Risks Related to Products Liability
We do not currently carry products liability insurance and we may not be
able to acquire sufficient coverage in the future to cover large claims.
Clinical trials, manufacturing and product sales may expose us to liability
claims from the use of the Delcath system. Though participants in clinical
trials are generally required to execute consents and waivers of liability, they
may still be able to assert products liability claims against us. Claims for
damages, whether or not successful, could cause delays in the clinical trials
and result in the loss of physician endorsement. A successful products liability
claim or recall would have a material adverse effect on our business, financial
condition and results of operations.
Risks Related to an Investment in Our Securities
The following factors relate to risks that are material to an investment in
our common stock. Any of these factors could result in lowering the market value
of our common stock and our warrants.
There is a limited public float of our common stock and of our 2000
Warrants 2003 Warrants. Because of this, trades of relatively small amounts of
our common stock can have a disproportionate effect on the market price for our
common stock. The market price of our common stock may be volatile.
Of our outstanding common stock, approximately two-thirds (including the
shares that could be sold by the selling security holders named herein) can be
considered to be in the public float. The term "public float" refers to shares
freely and actively tradeable on the Nasdaq Small Cap Market and/or the Boston
Stock Exchange and not beneficially owned by officers, directors or affiliates,
as such term is defined under the Securities Act. Because of the relatively
small public float and the limited trading volume of our common stock, purchases
and sales of relatively small amounts of our common stock can have a
disproportionate effect on the market price for our common stock. As a result,
the market price of our common stock can be volatile.
The number of shares eligible for future sale may cause the market price of
our common stock to be below the level it otherwise would.
The potential for sales of substantial amounts of our common stock, or
"equity overhang," could adversely affect the market price of our common stock.
As of April 15, 2004, 11,498,626 shares of our common stock were outstanding.
All of these shares (including the shares that could be sold by the selling
security holders named herein) will be freely tradable without restriction or
further registration under the Securities Act. However, the shares of our common
stock outstanding and held by our affiliates are subject to certain limitations
on resale without registration under the Securities Act. These shares are
eligible for sale in compliance with Rule 144. Rule 144 provides volume and
manner of sale restrictions and holding periods, which expire after the holder
of our common stock ceases to meet the definitions of affiliate or underwriter.
In addition, we may issue substantial amounts of common stock upon exercise
of options outstanding under our stock option plans.
Sales of substantial amounts of common stock following this offering, or
the perception that such sales could occur, could have an adverse effect on
prevailing market prices for our common stock and our publicly-traded warrants.
Anti-takeover provisions in our certificate of incorporation and by-laws
and under Delaware law and our stockholder rights agreement may reduce the
likelihood of a potential change of control.
-5-
Provisions of our certificate of incorporation, by-laws and Delaware law
may have the effect of discouraging, delaying or preventing a change in control
of us or unsolicited acquisition proposals that a stockholder might consider
favorable. These include provisions:
o providing for a classified board and permitting the removal of a
director only for cause;
o authorizing the board of directors to fill vacant directorships
or increase the size of our board of directors; and
o subjecting us to the provisions of Section 203 of the Delaware
General Corporate Law, which provides that a Delaware corporation
may not engage in any of a broad range of business combinations
with a person or entity who owns 15% or more of the outstanding
voting stock of that company for a period of three years from the
date the person or entity became an interested stockholder unless
(a) prior to such time the board of directors of the corporation
approved either the business combination or the transaction which
resulted in the stockholder's becoming an interested stockholder
or (b) upon consummation of the transaction which resulted in the
stockholder's becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the
corporation outstanding at the time the transaction commenced or
(c) at or subsequent to such time the business combination is
approved by the board of directors and authorized at an annual or
special meeting of stockholders by the affirmative vote of at
least 66 2/3% of the outstanding voting stock not owned by the
interested stockholder.
Furthermore, our board of directors has the authority to issue shares of
preferred stock in one or more series and to fix the rights and preferences of
the shares of any such series without stockholder approval. Any series of
preferred stock is likely to be senior to the common stock with respect to
dividends, liquidation rights and, possibly, voting rights. Our board's ability
to issue preferred stock may have the effect of discouraging unsolicited
acquisition proposals, thus adversely affecting the market price of our common
stock and warrants.
We also have a stockholder rights agreement which could have the effect of
substantially increasing the cost of acquiring us unless our board of directors
supports the transaction even if the holders of a majority of our common stock
are in favor of the transaction.
Our common stock is listed on the Nasdaq SmallCap Market. If we fail to
meet the requirements of The Nasdaq Stock Market for continued listing, our
common stock could be delisted.
Our common stock is currently listed on the Nasdaq SmallCap Market. To keep
such listing, we are required to maintain: (i) a minimum bid price of $1.00 per
share, (ii) a certain public float, (iii) a certain number of round lot
shareholders and (iv) one of the following: a net income from continuing
operations (in the latest fiscal year or two of the three last fiscal years ) of
at least $500,000, a market value of listed securities of at least $35 million
or a stockholders' equity of at least $2.5 million. At times, we have not met
one or more of these criteria. If we do not meet all of the applicable criteria,
our common stock could be delisted from the Nasdaq SmallCap Market.
If our common stock is delisted from the Nasdaq SmallCap Market, we may be
subject to the risks relating to penny stocks.
If our common stock were to be delisted from trading on the Nasdaq SmallCap
Market and the trading price of the common stock remains below $5.00 per share
on the date the common stock were delisted, trading in such securities would
also be subject to the requirements of certain rules promulgated under the
Exchange Act. These rules require additional disclosure by broker-dealers in
connection with any trades involving a stock defined as a penny stock and impose
various sales practice requirements on broker-dealers who sell penny stocks to
persons other than established customers and accredited investors, generally
-6-
institutions. The additional burdens imposed upon broker-dealers by such
requirements may discourage broker-dealers from effecting transactions in our
securities, which could severely limit the market price and liquidity of such
securities and the ability of purchasers to sell our securities in the secondary
market.
A penny stock is defined generally as any non-exchange listed equity
security that has a market price of less than $5.00 per share, subject to
certain exceptions.
California investors may not be able to resell the securities.
Our public offering in 2003 was approved in California on the basis of a
limited offering qualification. Investors who are residents of California must
meet a "super suitability" standard of not less than $250,000 liquid net worth
(exclusive of home, home furnishings and automobiles), plus $65,000 gross annual
income or $500,000 liquid net worth or $1,000,000 net worth (inclusive of home,
home furnishings and automobiles) or $200,000 gross annual income. We did not
have to demonstrate compliance with some or all of the merit regulations of the
California Department of Corporations, as found in Title 10, California Code of
Regulations, Rule 260.140 et seq.
Residents of the State of California may be unable to sell shares of common
stock they purchase in this offering, and investors residing in all other states
may be unable to sell shares of common stock they purchase in this offering to
California residents, pursuant to exemptions for secondary trading available
under California Corporations Code Section 25104(h), as such exemptions have
been withheld. However, secondary sales may be made to purchasers who meet the
"super suitability" standards or there may be other exemptions to cover private
sales by the bona fide owners of our securities for such owners' own account
without advertising and without being effected by or through a broker dealer in
a public offering.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements in this prospectus and in the documents incorporated
herein by reference, including statements of our expectations, o intentions,
plans, 3,098,070 objectives and beliefs, shares, are "forward-looking consisting
statements," within the of: meaning of Section 21E of 1,898,070 the Securities
Exchange shares Act of 1934, that are issuable subject to certain upon events,
risks and exercise of uncertainties that may be the outside our control.
currently These forward-looking outstanding statements may be 2003 identified by
the use of Warrants; words such as "expects," and "anticipates," "intends,"
1,200,000 "plans" and similar shares expressions. They issuable include
statements of our upon future plans and exercise of objectives for our future
the operations and statements currently of future economic outstanding
performance, information 2000 regarding our expected Warrants. growth, our
capital budget and future capital requirements, the availability of funds and
our ability to meet future capital needs, the realization of our deferred tax
assets and the assumptions described in this prospectus and in the documents
incorporated herein by reference underlying such forward-looking statements.
Actual results and developments could differ materially from those expressed in
or implied by such statements due to a number of factors, including those
described in the context of such forward-looking statements, our ability to
achieve operating efficiencies, industry pricing and technology trends, evolving
industry standards, domestic and international regulatory matters, general
economic and business conditions, the strength and financial resources of our
competitors, our ability to find and retain skilled personnel, the political and
economic climate in which we conduct operations, the risks discussed in "Risk
Factors" and other risk factors described from time to time in our other
documents and reports filed with the Securities and Exchange Commission. We do
not assume any responsibility to update any of our forward-looking statements
regardless of whether factors change as a result of new information, future
events or for any other reason. We advise you to review any additional
disclosures we make in our Form 10-KSB, Form 10-QSB and Form 8-K reports filed
with the SEC.
-7-
OUR BUSINESS
General
Since our founding in 1988, we have been a development stage company
engaged primarily in developing a drug-delivery system which is designed to
isolate the liver from the general circulatory system and to administer
chemotherapy and other therapeutic agents directly to the liver. Our objectives
are to establish the use of the Delcath system as the standard technique for
delivering chemotherapy agents to the liver and to expand the Delcath technology
so that it may be used in the treatment of other liver diseases and of cancers
in other parts of the body.
A more complete description of our business is contained in our Annual
Report on Form 10-KSB for the year ended December 31, 2003. See "Incorporation
of Certain Documents by Reference."
Corporate Information
Our executive offices are located at 1100 Summer Street, Stamford,
Connecticut 06905. Our telephone number at this location is (203) 323-8668. We
maintain a corporate website located at
http://www.delcathsystems.com. The contents of our website are not included as
part of this prospectus.
THE OFFERING
Common stock offered by o 3,098,070 shares, consisting of:
the Company 1,898,070 shares issuable upon
exercise of the currently
outstanding 2003 Warrants; and
1,200,000 shares issuable upon
exercise of the currently
outstanding 2000 Warrants;
Common Stock offered by the Selling o 240,000 shares issuable upon
Shareholders exercise ofthe outstanding unit
warrantsheld by Whale Securities
Co., L.P., the managing underwriter
of our initial public offering in
2000, or upon exercise of the
2000 Warrants that would be
issued upon exercise of the unit
warrants;
o 20,265 shares issued upon exercise
of warrants issued in connection
with a private placement to an
accredited investor in 2002;
o 677,410 shares issuable upon
exercise of the outstanding unit
warrants held by Roan/Myers
Associates, L.P., the managing
underwriter of our 2003 public
offering or its transferees, or
upon exercise of the 2003 Warrants
that would be issued upon exercise
of the unit warrants;
o 1,859,361 shares issued in
connection with private placements
in 2004 to accredited investors or
issuable upon exercise of warrants
issued to such investors; and
o 74,374 shares issuable upon
exercise of outstanding warrants
issued to the placement agents in
connection with the 2004 private
placements to accredited investors.
Shares outstanding at April 15, 2004 o 11,498,626 shares
Term of the 2000 Warrants o exercisable at any time until
October 18, 2005.
-8-
Term of the 2003 Warrants o exercisable at any time until
May 20, 2008.
Redemption o Our 2000 Warrants may be redeemed
at a price of $0.10 per warrant,
upon 30 days' notice, at any time,
provided that the closing bid
quotation of our common stock on
all 20 trading days ending on the
third day prior to the day on
which we give notice has been at
least 150% of the then effective
exercise price of the 2000 Warrants
and we have received the written
consent of Whale Securities Co.,
L.P., the lead underwriter of our
2000 public offering, for the
redemption.
o Commencing May 20, 2004, our 2003
Warrants may be redeemed at our
option at a redemption price of
$0.01 per warrant provided (i) the
average closing price of our common
stock for the 20 trading days prior
to the date of notice of redemption
is at least $1.24 and (ii) there is
then an effective registration
statement providing for the
issuance of the underlying shares
of common stock.
o Commencing one year from the
effective date of the registration
statement of which this prospectus
is a part, our 2004 Warrants may
be redeemed at our option at a
redemption price of $0.10 per
warrant provided (i) the average
per share market value of our
common stock for the 20 trading
days prior to the date of notice of
redemption is at least $6.02, (ii)
a registration statement providing
for the issuance of the underlying
shares of common stock is effective
and has been effective for at least
60 consecutive calendar days and
(iii) trading in our common stock
has not been suspended by the SEC
or the Nasdaq SmallCap Market.
Trading symbols of our publicly traded o Our common stock is traded on the
securities Nasdaq SmallCap Market and the
Boston Stock Exchange under the
symbols "DCTH" and "DCT,"
respectively.
o Our 2000 Warrants are traded on the
Nasdaq SmallCap Marker and the
Boston Stock Exchange under the
symbols "DCTHW" and "DCT,"
respectively.
o Our 2003 Warrants are traded on the
OTC Bulletin Board and the Boston
Stock Exchange under the symbols
"DCTHZ" and "DCT&W," respectively.
Terms of our Common Stock
As of April 15, 2004, there were 11,498,626 shares of our common stock
outstanding. Assuming all outstanding 2004 Warrants, 2003 Warrants (including
the unit warrants issued to the underwriters) and 2000 Warrants (including the
unit warrants issued to the underwriters) are exercised for the issuance of
4,461,726 shares of common stock, there would be 15,960,352 shares of common
stock outstanding.
Holders of common stock are entitled to one vote for each share on all
matters submitted to a stockholder vote. Holders of common stock do not have
cumulative voting rights. Therefore, holders of a majority of the shares of
common stock voting for the election of directors can elect all of the
directors. Holders of common stock are entitled to share in all dividends that
the board of directors, in its discretion, declares from legally available
funds. In any liquidation, dissolution or winding up of Delcath, each
-9-
outstanding share entitles its holder to participate pro rata in all assets that
remain after payment of liabilities and after providing for each class of stock,
if any, having preference over the common stock.
Holders of common stock have no conversion, preemptive or other
subscription rights and there are no redemption provisions applicable to the
common stock. The rights of the holders of common stock are subject to any
rights that may be fixed for holders of preferred stock, when and if any
preferred stock is issued. All outstanding shares of common stock are, and the
shares underlying all options and warrants will be, duly authorized, validly
issued, fully paid and non-assessable upon our issuance of these shares.
Terms of the 2004 Warrants
As of the date hereof, there were 446,246 outstanding 2004 Warrants
(including those issued to the placement agents in connection with the private
placements). In addition, each 2004 Warrant entitles the holder thereof to
purchase one share of common stock at a price of $3.01 per share. The 2004
Warrants are redeemable as described above under "The Offering."
Terms of the 2003 Warrants
As of the date hereof, there were 1,898,070 outstanding 2003 Warrants. Each
2003 Warrant entitles the holder thereof to purchase one share of common stock
at a price of $0.775 per share, subject to adjustment, at any time up to May 20,
2008. In addition each unit warrant held by Roan/Myers Associates, L.P. or its
transferees entitles the holder thereof to purchase five shares of our common
stock and five 2003 Warrants for a purchase price of $5.12. The 2003 Warrants
issuable upon exercise of the unit warrant would have the same terms as the
provisions of the other 2003 Warrants except that the exercise price of such
warrants is $1.28 per share. The 2003 Warrants are redeemable as described above
under "The Offering."
We expect to give a notice of redemption of the outstanding 2003 Warrants
as promptly as practicable following the date hereof. Under those circumstances
any holder of a 2003 Warrant who does not exercise his 2003 Warrant by the date
specified in the notice of redemption would receive a cash payment of $0.01 per
2003 Warrant and would not thereafter be able to exercise the 2003 Warrant.
The 2003 Warrants were issued in registered form under a warrant agent
agreement by and between Delcath and American Stock Transfer & Trust Company, as
warrant agent. Reference is made to the warrant agent agreement, dated as of May
20, 2003, which was filed as Exhibit 4.8 to Amendment No. 3 to the Company's
Registration Statement on Form SB-2 (No. 333-101661) for a complete description
of the terms and conditions thereof.
Terms of the 2000 Warrants
As of the date hereof, there were 1,200,000 outstanding 2000 Warrants. Each
2000 Warrant entitles the holder thereof to purchase one share of common stock
at a price of $6.60 per share, subject to adjustment, at any time up to October
15, 2005. Each unit warrant held by Whale Securities Co., L.P., the underwriter
for our 2000 initial public offering, entitles Whale Securities to purchase one
share of common stock and one 2000 Warrant at a price of $6.60. The 2000
Warrants issuable upon exercise of the unit warrant would have the same
provisions as the other 2000 Warrants except that the exercise price of such
warrants is $10.50 per share. The 2000 Warrants are redeemable as described
above under "The Offering."
The 2000 Warrants were issued in registered form under a warrant agreement
between and among Delcath, Whale Securities Co., L.P. and American Stock
Transfer & Trust Company, as warrant agent. Reference is made to the warrant
agreement which was filed as Exhibit 4.2 to Amendment No. 5 to the Company's
Registration Statement on Form SB-2 (No. 333-39470) for a complete description
of the terms and conditions thereof.
-10-
Transfer Agent
The transfer agent for our common stock, 2003 Warrants and 2000 Warrants is
American Stock Transfer & Trust Company. The Company acts as the transfer agent
for the 2004 Warrants and the unit warrants issued to Roan/Meyers Associates,
L.P. and to Whale Securities Co., L.P.
USE OF PROCEEDS
In the event that all of our outstanding 2003 Warrants and 2000 Warrants,
including unit warrants held by the underwriters of our 2003 and 2000 public
offerings, are exercised, we estimate that the net proceeds from the sale by us
of shares of our common stock being offered by this prospectus, after deducting
the estimated expenses of this offering will be approximately $9.3 million.
However, the actual number of warrants exercised will depend on numerous factors
beyond our control, including, without limitation, the market price of our
common stock. Based on the recent trading prices of our common stock, we believe
it is reasonable to assume that, if we call the 2003 Warrants for redemption in
accordance with their terms, a substantial portion of the 2003 Warrants will be
exercised. Whether other warrants are likely to be issued will probably depend
on the market prices of our common stock between the date hereof and the
expiration date of the particular warrant. We cannot estimate with reasonable
accuracy the number of such warrants which may be exercised and the amount of
proceeds to be received therefrom.
We expect that we would use any proceeds we receive upon exercise of any of
the 2003 Warrants and the 2000 Warrants (including any exercise by the managing
underwriters) for working capital purposes.
Although this prospectus does not cover our offer of common stock on
exercise of the 2004 Warrants, including the 2004 Warrants held by the placement
agents, we would also receive the proceeds of the exercise of the 2004 Warrants.
Prior to expenditure, proceeds will be invested principally in high grade,
short-term, interest-bearing instruments.
SELLING SHAREHOLDERS
The following table sets forth the number and percentage of shares that are
being registered by this Prospectus for the account of the entities listed below
(the "Selling Shareholders"). The shares may be sold by the Selling
Shareholders, or any of their assigns, pursuant to the exercise of some or all
of our currently outstanding 2004 Warrants, 2003 Warrants and 2000 Warrants from
time to time in the public marketplace. The Selling Shareholders are not
obligated to exercise any of their warrants. All information contained in the
table below is based on information provided to us by the Selling Shareholders,
and we have not independently verified this information. The Selling
Shareholders are not making any representation that the shares covered by this
prospectus will be offered for sale. The Selling Shareholders may from time to
time offer and sell pursuant to this prospectus any or all of the shares being
registered for resale.
The applicable percentages of ownership are based on an aggregate of
11,498,626 shares of our common stock issued and outstanding as of April 15,
2004 plus, in the case of each Selling Shareholder, the number of shares such
Selling Shareholder could acquire within 60 days on exercise of warrants. None
of the Selling Shareholders has had a material relationship with us, or with our
predecessors or affiliates, at any time during the past three years.
-11-
Shares
Beneficially Shares Beneficially Owned
Owned Prior to Shares Being After the Offering
Shareholder the Offering(1) Offered(2) Number Percent (%)
----------- -------------- ---------- ------ -----------
Whale Securities Co., L.P. 240,000 (3) 240,000 0 0%
Yenom Partners 20,265 20,265 0 0%
Roan/Myers Associates, L.P. 417,410 (4) 417,410 0 0%
Brian Herman 77,000 (5) 77,000 0 0%
James St. Clair 10,000 (6) 10,000 0 0%
Robert Dombrowski 4,000 (7) 4,000 0 0%
Zohar Hod 4,000 (8) 4,000 0 0%
Carlos Corzine 12,500 (9) 12,500 0 0%
Sterling Financial Investment
Group 12,500 (10) 12,500 0 0%
Imtiaz Khan 110,000 (11) 110,000 0 0%
Pryor, Counts & Co., Inc. 30,000 (12) 30,000 0 0%
AS Capital Partners, LLC 60,975 (13) 60,975 0 0%
Basso Equity Opportunity Fund
Ltd. 125,000 (14) 125,000 0 0%
Basso Multi-Strategy Holding
Fund Ltd 125,000 (15) 125,000 0 0%
Bristol Investment Fund, Inc. 142,635 (16) 142,635 0 0%
DKR Sound Shore Oasis Holding
Fund Ltd. 259,340 (17) 259,340 0 0%
Enable Growth Partners LP 129,670 (18) 129,670 0 0%
Iroquois Capital LP 103,735 (19) 103,735 0 0%
OTAPE Investments LLC 77,805 (20) 77,805 0 0%
SRG Capital, LLC 155,605 (21) 155,605 0 0%
Truk International Fund, LP 2,980 (22) 2,980 0 0%
Truk Opportunity Fund, LP 28,275 (23) 28,275 0 0%
Vertical Ventures LLC 285,270 (24) 285,270 0 0%
H. C. Wainwright & Co., Inc. 29,926 (25) 29,926 0 0%
John R. Clarke 9,260 (26) 9,260 0 0%
Scott F. Koch 9,260 (27) 9,260 0 0%
Jimmie Sundstrom 645 (28) 645 0 0%
Robert Nathan 9,260 (29) 9,260 0 0%
Ari J. Fuchs 1,500 (30) 1,500 0 0%
-12-
Shares
Beneficially Shares Beneficially Owned
Owned Prior to Shares Being After the Offering
Shareholder the Offering(1) Offered(2) Number Percent (%)
----------- -------------- ---------- ------ -----------
Stonestreet LP 155,601 (31) 155,601 0 0%
Omicron Master Trust 207,470 (32) 207,470 0 0%
MZM Capital Management 14,523 (33) 14,523 0 0%
(1) Unless otherwise noted, all of the shares shown are held by individuals or
entities possessing sole voting and investment power with respect to such
shares. Shares not outstanding but deemed beneficially owned by virtue of
the right of a person to acquire them within 60 days, by the exercise of
options or warrants or conversion of preferred stock, are deemed
outstanding in determining the number of shares beneficially owned by such
person. Because the Selling Shareholders may choose not to sell any of the
shares offered by this prospectus, and because there are currently no
agreements, arrangements or undertakings with respect to the sale of any of
the shares of common stock, we cannot estimate the number of shares that
the Selling Shareholders will hold after completion of the offering. For
purposes of this table, we have assumed that the Selling Shareholders will
have sold all of the shares covered by this prospectus upon the completion
of the offering.
(2) Assumes the sale of all shares of common stock issuable upon the exercise
of the 2004 Warrants, the 2003 Warrants and the 2000 Warrants issued to the
Selling Shareholders in connection with our 2004 private placements
(including the warrants issued to the placement agents) and our 2003 and
2000 public offerings (including the unit warrants issued to the managing
underwriters).
(3) Consists of 120,000 shares that could be purchased upon exercise of unit
warrants and 120,000 shares that could be purchased on exercise of the 2000
Warrants issuable on exercise of the unit warrants.
(4) Consists of 208,705 shares that could be purchased upon exercise of unit
warrants and 208,705 shares that could be purchased on exercise of the 2003
Warrants issuable on exercise of the unit warrants.
(5) Includes 31,000 shares that could be purchased upon exercise of unit
warrants and 38,500 shares that could be purchased on exercise of the 2003
Warrants issuable on exercise of the unit warrants.
(6) Includes 5,000 shares that could be purchased on exercise of the 2003
Warrants issued on exercise of the unit warrants.
(7) Includes 2,000 shares that could be purchased on exercise of the 2003
Warrants issued on exercise of the unit warrants.
(8) Consists of 2,000 shares that could be purchased upon exercise of unit
warrants and 2,000 shares that could be purchased on exercise of the 2003
Warrants issuable on exercise of the unit warrants.
(9) Consists of 6,250 shares that could be purchased upon exercise of unit
warrants and 6,250 shares that could be purchased on exercise of the 2003
Warrants issuable on exercise of the unit warrants.
(10) Consists of 6,250 shares that could be purchased upon exercise of unit
warrants and 6,250 shares that could be purchased on exercise of the 2003
Warrants issuable on exercise of the unit warrants.
-13-
(11) Consists of 55,000 shares that could be purchased upon exercise of unit
warrants and 55,000 shares that could be purchased on exercise of the 2003
Warrants issuable on exercise of the unit warrants.
(12) Includes 15,000 shares that could be purchased on exercise of the 2003
Warrants issued on exercise of the unit warrants.
(13) Includes 12,195 shares that could be purchased upon exercise of 2004
Warrants.
(14) Includes 25,000 shares that could be purchased upon exercise of 2004
Warrants.
(15) Includes 25,000 shares that could be purchased upon exercise of 2004
Warrants.
(16) Includes 28,527 shares that could be purchased upon exercise of 2004
Warrants.
(17) Includes 51,868 shares that could be purchased upon exercise of 2004
Warrants.
(18) Includes 25,934 shares that could be purchased upon exercise of 2004
Warrants.
(19) Includes 20,747 shares that could be purchased upon exercise of 2004
Warrants.
(20) Includes 15,561 shares that could be purchased upon exercise of 2004
Warrants.
(21) Includes 31,121 shares that could be purchased upon exercise of 2004
Warrants.
(22) Includes 596 shares that could be purchased upon exercise of 2004 Warrants.
(23) Includes 5,655 shares that could be purchased upon exercise of 2004
Warrants.
(24) Includes 57,054 shares that could be purchased upon exercise of 2004
Warrants.
(25) Consists of shares that could be purchased upon exercise of 2004 Warrants.
H. C. Wainwright & Co., Inc. ("HCW") received these securities as
compensation for its services as placement agent in connection with the
2004 private placement.
(26) Consists of shares that could be purchased upon exercise of 2004 Warrants.
Mr. Clarke, President of HCW, received these warrants from HCW in the
ordinary course of business and at the time of receiving the securities had
no agreements or understandings, directly or indirectly, with any person to
distribute them. HCW had received these securities as compensation for its
services as placement agent in the ordinary course of business and at the
time of receiving the securities had no agreements or understandings,
directly or indirectly, with any person to distribute them.
(27) Consists of shares that could be purchased upon exercise of 2004 Warrants.
Mr. Koch, a Managing Director of HCW, received these warrants from HCW in
the ordinary course of business and at the time of receiving the securities
had no agreements or understandings, directly or indirectly, with any
person to distribute them. HCW had received these securities as
compensation for its services as placement agent in the ordinary course of
business and at the time of receiving the securities had no agreements or
understandings, directly or indirectly, with any person to distribute them.
(28) Consists of shares that could be purchased upon exercise of 2004 Warrants.
Mr. Sundstrom, a Managing Director of HCW, received these warrants from HCW
in the ordinary course of business and at the time of receiving the
securities had no agreements or understandings, directly or indirectly,
with any person to distribute them. HCW had received these securities as
compensation for its services as placement agent in the ordinary course of
business and at the time of receiving the
-14-
securities had no agreements or understandings, directly or indirectly,
with any person to distribute them.
(29) Consists of shares that could be purchased upon exercise of 2004 Warrants.
Mr. Nathan, Senior Vice President of HCW, received these warrants from HCW
in the ordinary course of business and at the time of receiving the
securities had no agreements or understandings, directly or indirectly,
with any person to distribute them. HCW had received these securities as
compensation for its services as placement agent in the ordinary course of
business and at the time of receiving the securities had no agreements or
understandings, directly or indirectly, with any person to distribute them.
(30) Consists of shares that could be purchased upon exercise of 2004 Warrants.
Mr. Fuchs, an employee of HCW, received these warrants from HCW in the
ordinary course of business and at the time of receiving the securities had
no agreements or understandings, directly or indirectly, with any person to
distribute them. HCW had received these securities as compensation for its
services as placement agent in the ordinary course of business and at the
time of receiving the securities had no agreements or understandings,
directly or indirectly, with any person to distribute them.
(31) Includes 31,120 shares that could be purchased upon exercise of 2004
Warrants.
(32) Includes 41,494 shares that could be purchased upon exercise of 2004
Warrants.
(33) Consists of shares that could be purchased upon exercise of 2004 Warrants
issued to a placement agent.
PLAN OF DISTRIBUTION
The common stock offered by us hereby is issuable by us upon the exercise
of some or all of our currently outstanding 2003 Warrants and 2000 Warrants. The
balance of the common stock offered hereby may be offered for sale and sold from
time to time by the persons or entities described in this prospectus under the
heading "Selling Shareholders," or by pledgees, donees, transferees or other
successors in interest after the effective date of the registration statement of
which this prospectus is a part.
The Selling Shareholders, or their pledgees, donees, transferees or other
successors in interest, will act independently of us and of each other in making
decisions with respect to the timing, manner and size of each sale. Such sales
may be made on the Nasdaq SmallCap Market or otherwise, at prevailing prices and
on terms then prevailing or at prices related to the then market price, or in
negotiated transactions.
The manner in which the common stock offered hereby may be sold by the
Selling Shareholders include, without limitation, the following:
o block trades in which the broker-dealer(s) engaged by any of the
Selling Shareholders will attempt to sell common stock as agent but
may position or resell a portion of the block as principal to
facilitate the transaction;
o purchases by the broker-dealer(s) as principals and resale by such
broker-dealer(s) for their account pursuant to this prospectus;
o ordinary brokerage transactions and transactions in which the broker
solicits purchasers;
o negotiated transactions;
-15-
o a combination of any such methods of sale;
o through the writing or settlement of options or other hedging
transactions, whether through an options exchange or otherwise; or
o any other method permitted pursuant to applicable law.
In effecting sales, broker-dealers engaged by the Selling Shareholders may
arrange for other broker-dealers to participate.
In order to comply with the securities laws of certain states, if
applicable, the common stock offered hereby may be sold in such jurisdictions
only through registered or licensed brokers or dealers. In addition, in certain
states the common stock offered hereby may not be sold unless it has been
registered or qualified for sale in the applicable state or an exemption from
the registration or qualification requirement is available and is complied with
by us and the Selling Shareholders.
The Selling Shareholders and any brokers, dealers, agents or underwriters
who participate in the sale of the common stock offered hereby may be deemed to
be "underwriters" within the meaning of Section 2(11) of the Securities Act, and
the commissions paid or discounts allowed to any such brokers, dealers, agents
or underwriters, in addition to any profits received on resale of the common
stock offered hereby, if any such broker, dealer or agent should purchase any
common stock offered hereby as a principal, may be deemed to be underwriting
discounts or commissions under the Securities Act.
Under applicable rules under the Securities Exchange Act, any person
engaged in the distribution of the common stock may not simultaneously engage in
market making activities with respect to our common stock for a period of one
business day prior to the commencement of such distribution. In addition and
without limiting the foregoing, the Selling Shareholders will be subject to
applicable provisions of the Securities Exchange Act, and the rules thereunder,
including without limitation Regulation M, which provisions may limit the timing
of purchases and sales of common stock by the Selling Shareholders.
Although we will receive the proceeds of the exercise of the 2003 Warrants
and the 2000 Warrants (see "Use of Proceeds"), we will not receive any part of
the proceeds from the sale of the common stock offered hereby by the Selling
Shareholders. We are required to pay all fees and expenses incident to the
registration of the shares. However, we are not obligated to bear, and will not
bear, any underwriting discounts or commissions relating to the use by the
Selling Shareholders of an underwriter in connection with the disposition of the
common stock offered hereby by the Selling Shareholders.
We cannot assure you that the Selling Shareholders will sell any or all of
the common stock offered by them hereby. The common stock offered hereby by the
Selling Shareholders also may be sold pursuant to an available exemption from
the registration requirements of the Securities Act, including without
limitation Rule 144 promulgated thereunder. The sale of common stock by
"affiliates" (as defined in Rule 144(a) under the Securities Act) are subject to
the volume and manner of sale restrictions set forth in Rule 144.
We have agreed to indemnify the Selling Shareholders against certain
losses, claims, damages and liabilities, including liabilities under the
Securities Act.
LEGAL MATTERS
The validity of the common stock offered hereby has been passed upon for
Delcath by Murtha Cullina, LLP, New Haven, Connecticut, counsel for Delcath.
-16-
EXPERTS
Our financial statements as of December 31, 2003 and for each of the two
years in the period ended December 31, 2003 and cumulative from inception
(August 5, 1988) to December 31, 2003, appearing in our Annual Report on Form
10-KSB for the year ended December 31, 2003 have been audited by Eisner LLP,
independent registered public accounting firm, as set forth in their report
thereon dated February 11, 2004 except as to Note 6, the date of which is March
22, 2004, included therein and incorporated herein by reference. Such financial
statements are incorporated herein by reference in reliance upon such report
given upon the authority of such firm as experts in accounting and auditing.
WHERE CAN YOU FIND MORE INFORMATION
We file periodic reports under the Securities Exchange Act of 1934, as
amended, that include information about us. We have also filed with the U.S.
Securities and Exchange Commission in Washington, D.C., a registration statement
on Form S-3 under the Securities Act with the respect to the shares of common
stock offered by this prospectus. The registration statement relates to the
common stock offered by the Company upon exercise of the 2003 Warrants and the
2000 Warrants (including the warrants held by the managing underwriters of our
public offerings) and the resale of such shares, the shares we sold in our
private placements in 2002 and 2004 and the shares we would issue upon exercise
of the 2004 Warrants from time to time by the Selling Shareholders.
This prospectus does not contain all the information set forth in the
registration statement and the exhibits and schedules thereto. For further
information with respect to us and the common stock, we refer you to the
registration statement, the documents incorporated herein and the exhibits and
schedules filed therewith. The registration statement and the exhibits forming a
part thereof may be inspected without charge at the public reference facilities
maintained by the SEC at 450 Fifth Street, N.W., Washington, D.C. 20549 and
copies of such materials can be obtained from the Public Reference Section of
the SEC at 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates.
Please call the SEC at 1-800-SEC-0330 for further information regarding the
public reference facilities. In addition, the SEC maintains a website that
contains reports, proxy and information statements and other information
regarding registrants that file electronically with the SEC at http://
www.sec.gov.
Statements made in this prospectus as to the contents of any contract,
agreement or other document referred to are not necessarily complete. With
respect to each such contract, agreement or other document filed as an exhibit
to the registration statement, we refer you to the exhibit to the registration
statement referencing the item for a more complete description of the matter
involved, and each such statement is qualified in its entirety by reference
thereto. You may read and obtain a copy of the registration statement and its
exhibits and schedules from the SEC, as described in the preceding paragraph.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents that we have filed with the Securities and Exchange
Commission are incorporated into this prospectus by reference:
1. Our Annual Report on Form 10-KSB for the fiscal year ended December 31,
2003, filed on March 30, 2004;
2. Our definitive Proxy Statement dated April 29, 2004 distributed in
connection with our Annual Meeting of Shareholders to be held on June 15, 2004;
-17-
3. Our Quarterly Report on Form 10-QSB for the quarter ended March 31,
2004, filed on May 17, 2004;
4. The description of our common stock contained under the caption
"Description of Our Capital Stock and Other Securities - Units" in the
Prospectus included in the Registrant's Registration Statement on Form SB-2 (No.
333-101661), declared effective on May 15, 2003.
5. The description of our 2003 Redeemable Common Stock Purchase Warrants
contained under the caption "Description of Our Capital Stock and Other
Securities - Warrants - 2003 Warrants" in the Prospectus included in the
Registrant's Registration Statement on Form SB-2 (No. 333-101661).
6. The description of our 2000 Redeemable Common Stock Purchase Warrants
contained under the caption "Description of Our Capital Stock and Other
Securities - Warrants - 2000 Warrants" in the Prospectus included in the
Registrant's Registration Statement on Form SB-2 (No. 333-101661).
All documents that we file with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Securities Exchange Act of 1934 after the date of this
prospectus and prior to the filing of a post-effective amendment to the
registration statement of which this prospectus is a part that indicates that
all the common stock offered has been sold, or which deregisters all common
stock then remaining unsold hereunder, shall be incorporated by reference into
this prospectus and to be a part hereof (and of the registration statement) from
the date of filing of such documents. Any statement contained in this prospectus
will be deemed to be modified or superseded for purposes of this prospectus to
the extent that a statement contained in any subsequently filed document which
also is or is deemed to be incorporated by reference herein modifies or
supersedes such statement. Any such statement so modified or superseded will not
be deemed, except as so modified or superseded, to constitute a part of this
prospectus.
To the extent that an independent auditor audits and reports on our
financial statements issued at future dates and consents to the use of its
reports thereon, such financial statements shall also be incorporated by
reference in this prospectus (and the registration statement) in reliance upon
their reports and their authority as experts in accounting and auditing.
We will provide without charge to each person, including any beneficial
owner, to whom a copy of this prospectus is delivered, upon written or oral
request, a copy of any and all information that has been incorporated by
reference herein (other than exhibits to such information, unless such exhibits
are specifically incorporated into any such information). Requests should be
directed to us at 1100 Summer Street, Stamford, Connecticut 06905, Attention:
Paul M. Feinstein, Chief Financial Officer. Mr. Feinstein may also be contacted
at (203) 323-8668.
DISCLOSURE OF THE SEC'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT
LIABILITIES
Our certificate of incorporation provides that we must, to the fullest
extent permitted or required by the Delaware General Corporation Law, indemnify
any and all persons whom we have the power to indemnify from and against any and
all of the expenses, liabilities or other matters referred to in or covered by
the Delaware General Corporation Law. The indemnification provided for in our
certificate of incorporation is not exclusive of any other rights to which those
indemnified may be entitled under any law, agreement, vote of shareholders or
disinterested directors or otherwise.
Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to our directors, officers and controlling persons pursuant to
the foregoing provisions or otherwise, we have been advised that in the opinion
of the SEC such indemnification is against public policy as expressed in the
Securities Act of 1933 and is, therefore, unenforceable.
-18-
Part II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The following table sets forth an itemization of all estimated expenses
payable in connection with the distribution of the securities being registered.
All of the expenses set forth below are estimates except for the SEC
registration fee. All of these expenses will be paid by the Company.
SEC registration fee $ 2,187
Legal fees and expenses 37,000
Accounting fees and expenses 7,500
Printing expenses 3,000
Miscellaneous 313
-----------------
Total $50,000
=================
Item 16. Exhibits
Number Description
3.1 Amended and Restated Certificate of Incorporation of Delcath Systems,
Inc. (incorporated by reference to Exhibit 3.1 to Registrant's Annual
Report on Form 10-KSB for the year ended December 31, 2002 (File No.
001-16133)).
3.2 Amended and Restated By-Laws of Delcath Systems, Inc. (incorporated by
reference to Exhibit 3.2 to Amendment No. 1 to Registrant's
Registration Statement on Form SB-2 (Registration No. 333-39470)).
4.1 Form of Underwriter's Unit Warrant Agreement (incorporated by
reference to Exhibit 4.1 to Amendment No. 1 to Registrant's
Registration Statement on Form SB-2 (Registration No. 333-101661)).
4.2 Form of Warrant Agent Agreement by and between Delcath Systems, Inc.
and American Stock Transfer & Trust Company, as warrant agent with
respect to the 2003 Warrants (incorporated by reference to Exhibit 4.8
to Amendment No. 3 to Registrant's Registration Statement on Form SB-2
(No. 333-101661)).
4.3 Form of Warrant Agreement by and between Delcath Systems, Inc. and
Whale Securities Co., L.P. (incorporated by reference to Exhibit 4.2
to Amendment No. 5 to Registrant's Registration Statement on Form SB-2
(Registration No. 333-39470)).
4.4 Form of Warrant Agreement by and between American Stock Transfer &
Trust Company, as warrant agent, Whale Securities Co., L.P. and
Delcath Systems, Inc. (incorporated by reference to Exhibit 4.3 to
Amendment No. 5 to Registrant's Registration Statement on Form SB-2
(Registration No. 333-39470)).
4.5 Rights Agreement, dated October 30, 2001, by and between Delcath
Systems, Inc. and American Stock Transfer & Trust Company, as Rights
Agent (incorporated by reference to Exhibit 4.7 to Registrant's Form
8-A dated November 12, 2001 (Commission File No. 001-16133)).
II-1
4.6 Form of Warrant to Purchase Shares of Common Stock issued pursuant to
the Common Stock Purchase Agreement dated as of March 19, 2004
(incorporated by reference to Exhibit 4 to Registrant's Current Report
on Form 8-K dated March 19, 2004).
5 Opinion of Murtha Cullina LLP.
10.1 Common Stock Purchase Agreement dated as of March 19, 2004 by and
among Delcath Systems, Inc. and the Purchasers Listed on Exhibit A
thereto (incorporated by reference to Exhibit 10.1 to Registrant's
Current Report on Form 8-K dated March 19, 2004).
10.2 Registration Rights Agreement dated as of March 19, 2004 by and among
Delcath Systems, Inc. and the Purchasers Listed on Schedule I thereto
(incorporated by reference to Exhibit 10.2 to Registrant's Current
Report on Form 8-K dated March 19, 2004).
23.1 Consent of Eisner LLP.
23.2 Consent of Murtha Cullina LLP (included in Exhibit 5).
24 Power of Attorney.
II-2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this amendment to its
registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Stamford, State of Connecticut this 9th day of
June, 2004.
Delcath Systems, Inc.
By: /s/ M. S Koly
----------------------------------
Name: M. S Koly
Title: President and Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1933, this amendment
to the registration statement has been signed by the following persons in the
capacities and on the date indicated.
Name Title
M. S. Koly President and Chief Executive )
------------------- Officer and Director (Principal )
Executive Officer) )
Paul M. Feinstein Chief Financial Officer )
------------------- (Principal Financial and ) By: /s/ M. S. Koly
Accounting Officer) ) -----------------
Attorney-in-Fact
)
Samuel Herschkowitz Chairman and Director )
-------------------- )
) Dated: June 9, 2004
Mark A. Corigliano Director )
-------------------- )
)
Daniel Isdaner Director )
-------------------- )
)
Victor Nevins Director )
-------------------- )
II-3
EXHIBIT INDEX
Number Description
3.1 Amended and Restated Certificate of Incorporation of Delcath Systems,
Inc. (incorporated by reference to Exhibit 3.1 to Registrant's Annual
Report on Form 10-KSB for the year ended December 31, 2002 (File No.
001-16133)).
3.2 Amended and Restated By-Laws of Delcath Systems, Inc. (incorporated by
reference to Exhibit 3.2 to Amendment No. 1 to Registrant's
Registration Statement on Form SB-2 (Registration No. 333-39470)).
4.1 Form of Underwriter's Unit Warrant Agreement (incorporated by
reference to Exhibit 4.1 to Amendment No. 1 to Registrant's
Registration Statement on Form SB-2 (Registration No. 333-101661)).
4.2 Form of Warrant Agent Agreement by and between Delcath Systems, Inc.
and American Stock Transfer & Trust Company, as warrant agent with
respect to the 2003 Warrants (incorporated by reference to Exhibit 4.8
to Amendment No. 3 to Registrant's Registration Statement on Form SB-2
(No. 333-101661)).
4.3 Form of Warrant Agreement by and between Delcath Systems, Inc. and
Whale Securities Co., L.P. (incorporated by reference to Exhibit 4.2
to Amendment No. 5 to Registrant's Registration Statement on Form SB-2
(Registration No. 333-39470)).
4.4 Form of Warrant Agreement by and between American Stock Transfer &
Trust Company, as warrant agent, Whale Securities Co., L.P. and
Delcath Systems, Inc. (incorporated by reference to Exhibit 4.3 to
Amendment No. 5 to Registrant's Registration Statement on Form SB-2
(Registration No. 333-39470)).
4.5 Rights Agreement, dated October 30, 2001, by and between Delcath
Systems, Inc. and American Stock Transfer & Trust Company, as Rights
Agent (incorporated by reference to Exhibit 4.7 to Registrant's Form
8-A dated November 12, 2001 (Commission File No. 001-16133)).
4.6 Form of Warrant to Purchase Shares of Common Stock issued pursuant to
the Common Stock Purchase Agreement dated as of March 19, 2004
(incorporated by reference to Exhibit 4 to Registrant's Current Report
on Form 8-K dated March 19, 2004).
5 Opinion of Murtha Cullina LLP.
10.1 Common Stock Purchase Agreement dated as of March 19, 2004 by and
among Delcath Systems, Inc. and the Purchasers Listed on Exhibit A
thereto (incorporated by reference to Exhibit 10.1 to Registrant's
Current Report on Form 8-K dated March 19, 2004).
10.2 Registration Rights Agreement dated as of March 19, 2004 by and among
Delcath Systems, Inc. and the Purchasers Listed on Schedule I thereto
(incorporated by reference to Exhibit 10.2 to Registrant's Current
Report on Form 8-K dated March 19, 2004).
23.1 Consent of Eisner LLP.
23.2 Consent of Murtha Cullina LLP (included in Exhibit 5).
24 Power of Attorney.